As the Chief Executive Officer of Genethon, Frédéric Revah has more than twenty years’ experience in the pharmaceutical and biotech industries as well as in academic research. Immediately prior to joining Genethon in January 2010, he had been Chief Executive Officer at Sepal Pharma (oncology), before which he was CEREP’s Vice-President of Drug Discovery and Scientific Director from 1999-2007, as well as being Chief Executive Officer of its oncology arm. He was also head of the CNS Gene Therapy Department and the Neurochemistry Department at Rhône-Poulenc Rorer (now Sanofi-Aventis) from 1992 to 1998.
Frédéric Revah started his career as an associate staff researcher at the Institut Pasteur (from 1990 to 1992). He obtained his doctorate at the Institut Pasteur / Université de Paris V in 1991, and graduated from the Ecole Polytechnique engineering school in 1985.